Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation

A Multicentre, Multinational, Placebo-controlled, Double-blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00623701

Acronym

ALLEGRA6

Enrollment

126

Registered

2008-02-26

Start date

2008-03-31

Completion date

2012-10-31

Last updated

2013-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy, Conjunctivitis, Rhinitis

Keywords

sublingual grass pollen preparation, IgE-mediated Allergic Disease attributed to grass pollen

Brief summary

Efficacy and Safety from a high-dosed sublingual grass pollen preparation

Interventions

BIOLOGICALAllerslit forte

sublingual placebo preparation, daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Allergic rhinoconjunctivitis attributable to grass pollen * Positive SPT * Positive EAST * Positive provocation Test

Exclusion criteria

* Serious chronic disease * other perennial allergies

Design outcomes

Primary

Measure	Time frame
Symptom and Medication Score	Grass pollen season 2009

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026